Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) protein tyrosine kinases co-expressed in various cancers such as ovarian, breast, colon, and prostate subtypes. Herein, new TAK-285 derivatives (9a–h) were synthesised, characterised, and biologically evaluat...

Full description

Bibliographic Details
Main Authors: Seohyun Son, Ahmed Elkamhawy, Anam Rana Gul, Ahmed A. Al‐Karmalawy, Radwan Alnajjar, Ahmed Abdeen, Samah F. Ibrahim, Saud O. Alshammari, Qamar A. Alshammari, Won Jun Choi, Tae Jung Park, Kyeong Lee
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
EGFR/HER2
chemical synthesis
apoptosis
kinase panel
prostate carcinoma
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2023.2202358

Internet

https://www.tandfonline.com/doi/10.1080/14756366.2023.2202358

Similar Items